3D Medicines (HKSE:01244) Liabilities-to-Assets : 0.39 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. 3D Medicines's Total Liabilities for the quarter that ended in Dec. 2023 was HK$610.5 Mil. 3D Medicines's Total Assets for the quarter that ended in Dec. 2023 was HK$1,562.9 Mil. Therefore, 3D Medicines's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 was 0.39.

3D Medicines Liabilities-to-Assets Historical Data

The historical data trend for 3D Medicines's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Medicines Liabilities-to-Assets Chart

3D Medicines Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Liabilities-to-Assets

3.56

3.14

0.33

0.39

3D Medicines Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Liabilities-to-Assets	Get a 7-Day Free Trial			3.14	-	0.33	0.39	0.39

Competitive Comparison of 3D Medicines's Liabilities-to-Assets

For the Biotechnology subindustry, 3D Medicines's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

3D Medicines's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3D Medicines's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where 3D Medicines's Liabilities-to-Assets falls into.

3D Medicines Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

3D Medicines's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )	=	Total Liabilities	/	Total Assets
	=	610.544	/	1562.881
	=	0.39

3D Medicines's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 is calculated as

Liabilities-to-Assets (Q: Dec. 2023 )	=	Total Liabilities	/	Total Assets
	=	610.544	/	1562.881
	=	0.39

3D Medicines (HKSE:01244) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

3D Medicines Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of 3D Medicines's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

3D Medicines (HKSE:01244) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » Liabilities-to-Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN

Website

https://www.3d-medicines.com

3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization of drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life.

Executives

Gong Zhaolong	2101 Beneficial owner
Zhu Pai	2101 Beneficial owner
Dragon Prosper Holdings Limited	2101 Beneficial owner
Simcere Pharmaceutical Group Limited	2101 Beneficial owner
Gong Zhaolong	2501 Other
Immunal Medixin Us Limited	2101 Beneficial owner
Kastle Limited
Shanghai Zhenlu Enterprise Management Consulting Partnership (limited Partnership)	2101 Beneficial owner
Shenzhen Efung Holding Co., Ltd.	2201 Interest of corporation controlled by you
Shenzhen Efung Investment Management Enterprise (l.p.)	2201 Interest of corporation controlled by you
Shenzhen Efung Ruishi Investment Enterprise (limited Partnership)	2201 Interest of corporation controlled by you
Zhu Jinqiao	2103 Interests held jointly with another person

3D Medicines (HKSE:01244) Headlines

No Headlines